Department of Breast Surgery, Fujian Medical University Union Hospital, No.29, Xin Quan Road, Gulou District, Fuzhou, Fujian Province, 350001, China.
Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, 350001, China.
BMC Geriatr. 2023 Oct 6;23(1):625. doi: 10.1186/s12877-023-04341-y.
BACKGROUND: This study aimed to investigate the role of post-mastectomy radiotherapy (PMRT) in the female aged 70 years or older diagnosed with breast cancer, which is still controversial. METHODS: This retrospective study enrolled female breast cancer women aged 70 + years following mastectomy from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM) was performed to reduce covariable imbalance. A nomogram was created to predict the 1,3,5-years overall survival (OS) and divide patients into three risk groups. RESULTS: After matching, PMRT were associated with significant improvement in breast cancer-specific survival (BCSS) and OS (p < 0.001). By contrast, the BCSS and OS benefit from PMRT were not significant in patients with T1N1 tumor (BCSS: HR = 0.716, p = 0.249;OS:HR = 0.908, p = 0.572), and T2N1 tumor (BCSS:HR = 0.866, p = 0.289;OS:HR = 0.879, p = 0.166). Stratified by subtype, the HR+/HER-2- subtype and the HR-/HER-2- subtype (all p < 0.001) have a significant prolonged survival, yet not significant BCSS difference are shown in the HER-2 + tumor. In the low-risk group as determined by the nomogram, the use of PMRT did not significantly improve OS (p = 0.203). CONCLUSIONS: This study demonstrated that PMRT improves the survival of females with elderly breast cancer, while for T1-2N1 breast cancer patients, the omission of PMRT could be considered. Furthermore, the nomogram we constructed could be used as a decision tool for the omission of PMRT in low-risk elderly patients.
背景:本研究旨在探讨 70 岁及以上女性乳腺癌患者行保乳术后放疗(PMRT)的作用,这仍存在争议。
方法:本回顾性研究纳入了来自监测、流行病学和最终结果(SEER)数据库的 70 岁以上行乳房切除术的女性乳腺癌患者。采用倾向评分匹配(PSM)来减少协变量的不平衡。建立列线图预测 1、3、5 年总生存率(OS),并将患者分为三个风险组。
结果:匹配后,PMRT 与乳腺癌特异性生存率(BCSS)和 OS 的显著改善相关(p<0.001)。相比之下,T1N1 肿瘤(BCSS:HR=0.716,p=0.249;OS:HR=0.908,p=0.572)和 T2N1 肿瘤(BCSS:HR=0.866,p=0.289;OS:HR=0.879,p=0.166)患者中,PMRT 的 BCSS 和 OS 获益并不显著。按亚型分层,HR+/HER-2-亚型和 HR-/HER-2-亚型(均 p<0.001)均有显著的生存延长,但 HER-2+肿瘤中未显示出显著的 BCSS 差异。在列线图确定的低危组中,PMRT 的使用并未显著改善 OS(p=0.203)。
结论:本研究表明,PMRT 可改善老年女性乳腺癌患者的生存,而对于 T1-2N1 期乳腺癌患者,可考虑省略 PMRT。此外,我们构建的列线图可作为在低危老年患者中省略 PMRT 的决策工具。
Curr Oncol Rep. 2021-1-2
Adv Cancer Res. 2020-2-29
CA Cancer J Clin. 2020-1-8